Marta Garrote

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.

Journal: Journal for immunotherapy of cancer

Published: November 25, 2025

Copy-Neutral Loss of Heterozygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

Copy-Neutral Loss of Heterozygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

Journal: The Journal of molecular diagnostics : JMD

Published: September 09, 2025

Copy-Neutral Loss of Heterzygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

Copy-Neutral Loss of Heterzygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

Journal: The Journal of molecular diagnostics : JMD

Published: September 09, 2025

Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia.

Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia.

Journal: HemaSphere

Published: September 04, 2025

Prognostic value of factor VIII, D-dimer and high molecular risk variants assessing re-thrombosis risk in non-cirrhotic portal vein thrombosis.

Prognostic value of factor VIII, D-dimer and high molecular risk variants assessing re-thrombosis risk in non-cirrhotic portal vein thrombosis.

Journal: JHEP reports : innovation in hepatology

Published: August 18, 2025

Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling.

Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling.

Journal: Blood advances

Published: August 04, 2025

Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis.

Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis.

Journal: Thrombosis and haemostasis

Published: January 14, 2025

Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.

Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.

Journal: Leukemia

Published: July 12, 2024

Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Journal: Leukemia

Published: June 19, 2024

Whole Exome Sequencing of Intermediate-Risk Acute Myeloid Leukemia without Recurrent Genetic Abnormalities Offers Deeper Insights into New Diagnostic Classifications.

Whole Exome Sequencing of Intermediate-Risk Acute Myeloid Leukemia without Recurrent Genetic Abnormalities Offers Deeper Insights into New Diagnostic Classifications.

Journal: International journal of molecular sciences

Published: June 17, 2024

Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes.

Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes.

Journal: Blood neoplasia

Published: May 06, 2024

A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3 inhibition.

A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3 inhibition.

Journal: Leukemia & lymphoma

Published: December 20, 2023

Showing 1-12 of 35

Last Updated: 09/26/2026